PsilodexMedication × psilocybin
Your list
General prescriptions
Brand names
Ery-Tab, Erythrocin, PCE, E.E.S.
Reviewed 2026-10-02

Erythromycin

psilodex.org/m/erythromycin · data v2026.10.02

Clinical contraindication
None listed
No clinical contraindication identified.
Best available evidence
Mechanism only
Half-life
Not recorded
Named in state rules?
CONot named
ORNot named
NMPending
Cite asPsilodex: erythromycin · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Th

Prolongs the QT interval, with torsades de pointes reported; risk stacks with other QT-prolonging drugs. Also a CYP3A4 inhibitor; CYP3A4 contributes to psilocin metabolism in vitro, so psilocin exposure could rise somewhat in theory.

Human data with psilocybin
None known: no published human data with psilocybin
Evidence types on this record
ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports
QT-prolonging
Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

2
  1. Ery-Tab (Erythromycin) Tablet, Delayed Release · FDA label (DailyMed) — Warnings: QT Prolongation; Precautions: CYP3A substrate and inhibitor
  2. Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — CYP2D6 and CYP3A4 metabolize psilocin in vitro; CYP2D6 genotype did not change psilocin plasma levels in humans

Record history

  • v2026.10.02First published.
  • 2026-10-02Last reviewed against its sources.

Report an error in this record →

Before you startTerms v2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Starting, stopping, or changing a medication is the prescriber's decision. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.